%0 Journal Article %T Clinical development and approval of second generation ALK inhibitors for ALK rearranged lung cancer %A Costa, Daniel B. %J Translational Lung Cancer Research %D 2014 %B 2014 %9 %! Clinical development and approval of second generation ALK inhibitors for ALK rearranged lung cancer %K %X Lung cancers are heterogeneous tumors often characterized by mutations in oncogenes and tumor suppressor genes. Anaplastic lymphoma kinase ( ALK ) genomic aberrations were first identified in non-small cell lung cancer (NSCLC) in 2007 (1). We now know that a substantial fraction (approximately 5%) of all NSCLCs harbor rearrangements between ALK and fusion partners (such as EML4 , TFG , KIF5B , KLC1 among others). %U https://tlcr.amegroups.org/article/view/3041 %V 3 %N 6 %P 373-375 %@ 2226-4477